Stocks to watch at the open
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
ResMed (RMD)
ResMed’s September quarter earnings per share of 56 cents missed analyst estimates of 58 cents per share, sending the stock down 1.4% in trade on the New York Stock Exchange.
Earnings per share increased 14% from the previous September quarter, driven by reporting record revenue for the quarter. All up, the numbers were positive for ResMed, the market simply expected a better result.
Domestically, ResMed is trading at its highest level since the share price collapsed in August 2010.
Current analyst target prices are comfortably over $6 – ResMed closed at $5.90 yesterday.
Transfield Services (TSE)
Since reporting the sale of its share in a New Zealand joint venture with Worley Parsons (WOR), Transfield has gained 8.8%. Market enthusiasm has been focused on the marginal reduction to gearing levels, which remain high in an uncertain environment.
The project manager holds their annual general meeting today. Both resource and government-related maintenance work has been soft this financial year and could impact Transfield’s guidance for the year ahead
Tone of messaging concerning the financial year so far and any forward guidance will direct the direction of trade for Transfield today.
Call 1300 880 160
Start a chat
Schedule a call
